Recent studies have converged on the intersection of glucagon-like peptide-1|GIP|GCGR activator therapies and DA neurotransmission. While GIP activators are commonly employed for addressing type 2 diabetes, their emerging consequences on reinforcement circuits, specifically mediated by dopaminerg